explore -WSS

explore

author：comprehensive 2025-09-14 21:43:33 - browse：5215

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine?

That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

“We have a very early think tank on: what would it take us, from a technology point of view and from an ecosystem point of view, to make long-lasting GLP-1 molecules?” Marcus Schindler, Novo’s chief scientific officer, said in an interview with STAT Wednesday. “Could we think about vaccine-like properties, where imagine you had, once a year, an injection with an equivalent of a GLP-1 that really helps you to maintain weight loss and have cardiovascular benefits?”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： Congress needs to close a vaccine

focus

hotspot

WSS

The most pressing bird flu mysteries scientists want answered

What Mike Pence has said that could be used in a Donald Trump trial

Eli Lilly’s Zepbound improved liver scarring in mid

ProMED, early warning system on disease outbreaks, in peril

Medicare Advantage's lean provider networks lead CMS complaints

FDA approves Moderna’s RSV vaccine, its second licensed product

focus

explore

focus

In age of alternative facts, a scholarly course on calling out crap

Microsoft strikes partnership with Duke Health to advance health AI

Medical leaders decry Supreme Court decision on affirmative action

Take antibiotics after sex, CDC recommends for certain risk groups

Medicare proposal to cover medical devices draws a mixed reaction

Senators tussle over abortion against the backdrop of a presidential campaign

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Medicare Advantage's lean provider networks lead CMS complaints

Medicare details structure of new drug price negotiation program

Wild otter attack leads to woman being airlifted to hospital, 2 others treated for injuries

focus

Illumina board agrees to spin off Grail, as divestment plans proceed

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Congress needs to close a vaccine

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Fight over Supreme Court dialysis ruling puts kidney patients at risk

UnitedHealth CEO's Medicaid comments send insurer stocks diving

leisure time

focus

hotspot

focus